KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash & Equivalents: 2013-2024

Historic Cash & Equivalents for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2024 value amounting to $58.5 million.

  • Travere Therapeutics' Cash & Equivalents rose 204.68% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year increase of 204.68%. This contributed to the annual value of $58.5 million for FY2024, which is 0.62% up from last year.
  • As of FY2024, Travere Therapeutics' Cash & Equivalents stood at $58.5 million, which was up 0.62% from $58.2 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Cash & Equivalents registered a high of $165.8 million during FY2021, and its lowest value of $58.2 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $59.5 million, with a median of $58.5 million in 2024.
  • As far as peak fluctuations go, Travere Therapeutics' Cash & Equivalents surged by 95.53% in 2021, and later plummeted by 62.78% in 2022.
  • Over the past 5 years, Travere Therapeutics' Cash & Equivalents (Yearly) stood at $84.8 million in 2020, then surged by 95.53% to $165.8 million in 2021, then tumbled by 62.78% to $61.7 million in 2022, then decreased by 5.69% to $58.2 million in 2023, then rose by 0.62% to $58.5 million in 2024.